REVIEW ARTICLE
Free to Read
Breast cancer—The catalyst of contemporary trials design
Zahraa Al-Hilli MD,
Anna Weiss MD,
Ava Armani MD,
Judy C Boughey MD,
Sarah L. Blair MD,
Zahraa Al-Hilli MD
Department of Surgery, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorAnna Weiss MD
Department of Surgery, Brigham and Women Hospital, Boston, Massachusetts, USA
Search for more papers by this authorAva Armani MD
Department of Surgery, University of California San Diego, San Diego, California, USA
Search for more papers by this authorJudy C Boughey MD
Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorCorresponding Author
Sarah L. Blair MD
Department of Surgery, University of California San Diego, San Diego, California, USA
Correspondence Sarah L. Blair, MD, University of California San Diego, 3855 Health Science Dr, La Jolla, CA 92093-0987, USA.
Email: [email protected]
Search for more papers by this authorZahraa Al-Hilli MD,
Anna Weiss MD,
Ava Armani MD,
Judy C Boughey MD,
Sarah L. Blair MD,
Zahraa Al-Hilli MD
Department of Surgery, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorAnna Weiss MD
Department of Surgery, Brigham and Women Hospital, Boston, Massachusetts, USA
Search for more papers by this authorAva Armani MD
Department of Surgery, University of California San Diego, San Diego, California, USA
Search for more papers by this authorJudy C Boughey MD
Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorCorresponding Author
Sarah L. Blair MD
Department of Surgery, University of California San Diego, San Diego, California, USA
Correspondence Sarah L. Blair, MD, University of California San Diego, 3855 Health Science Dr, La Jolla, CA 92093-0987, USA.
Email: [email protected]
Search for more papers by this authorFirst published: 13 December 2021
Abstract
Surgical trials in breast cancer have catalyzed contemporary trial design for solid organ cancers and are a prime example of surgeons taking the lead in clinical trial design. Surgeons have lead trials that have improved patient outcomes and quality of life without sacrificing oncologic safety. We have evolved from radical mastectomy to breast conservation and sentinel node biopsy. Contemporary trial design in breast cancer now focus on personalizing care based on tumor genomics
REFERENCES
- 1Fisher B, Jeong J-H, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002; 347(8): 567-575.
- 2Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16): 1233-1241.
- 3Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001; 30: 96-102.
- 4Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21(22): 4165-4174.
- 5Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010; 11(10): 927-933.
- 6Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305(6): 569-575.
- 7Giuliano AE, McCall L, Beitsch P. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg. 2010; 252(3): 426-433.
- 8Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013; 310(14): 1455-1461.
- 9Rosenkranz KM, Ballman K, McCall L, et al. The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: an initial report from ACOSOG Z11102 (Alliance) trial. Ann Surg Oncol. 2018; 25(10): 2858-2866.
- 10A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. Available from: https://clinicaltrials.gov/ct2/show/NCT01901094. Accessed: 20th October 2021.
- 11Wu C A leading lady [Internet]. Yesterday & Today: Available from https://www.cancertodaymag.org/Pages/Fall2012/betty-ford-yesterday-and-today.aspx. Accessed 20th October 2021.
- 12JMG W, Jungner G. Principals and practice of screening for disease [Internet]. World Health Organization Public Health Papers. 1968. Available from: https://apps.who.int/iris/bitstream/handle/10665/37650/WHO_PHP_34.pdf?sequence=17%26;isAllowed=y. Accessed 20th October 2021.
- 13Gastrin G, Miller AB, To T, et al. Incidence and mortality from breast cancer in the mama program for breast screening in Finland, 1973-1986. Cancer. 1994; 73(8): 2168-2174.
10.1002/1097-0142(19940415)73:8<2168::AID-CNCR2820730822>3.0.CO;2-V CAS PubMed Web of Science® Google Scholar
- 14Maddox WA, Carpenter JT Jr, Laws HL, et al. A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg. 1983; 198(2): 207-212.
- 15Robinson GN, van Heerden JA, Payne WS, Taylor WF, Gaffey TA. The primary surgical treatment of carcinoma of the breast: a changing trend toward modified radical mastectomy. Mayo Clin Proc. 1976; 51(7): 433-442.
- 16Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy. Cancer. 2003; 98(4): 697-702.
- 17van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000; 92(14): 1143-1150.
- 18Bendifallah S, Werkoff G, Borie-Moutafoff C, et al. Multiple synchronous (multifocal and multicentric) breast cancer: Clinical implications. Surg Oncol. 2010; 19(4):e115-e123.
- 19Gentilini O, Botteri E, Rotmensz N, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat. 2009; 113(3): 577-583.
- 20Hartsell WF, Recine DC, Griem KL, Cobleigh MA, Witt TR, Murthy AK. Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy? Int J Radiat Oncol. 1994; 30(1): 49-53.
- 21Cho LC, Senzer N, Peters GN. Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers. Am J Surg. 2002; 183(6): 650-654.
- 22Haley MM, Garces YI, Kee AY, et al. Breast conservation therapy (BCT) in multifocal vs. unifocal early stage breast cancer patients: the mayo experience. Int J Radiat Oncol. 2007; 69(3): S208-S209.
- 23Rosenkranz KM, Ballman K, McCall L, et al. Cosmetic outcomes following breast-conservation surgery and radiation for multiple ipsilateral breast cancer: data from the alliance Z11102 study. Ann Surg Oncol. 2020; 27(12): 4650-4661.
- 24Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007; 25(24): 3657-3663.
- 25Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg. 2012; 36(9): 2239-2251.
- 26Morrow M, Van Zee KJ, Patil S, et al. Axillary dissection and nodal irradiation can be avoided for most node-positive Z0011-eligible breast cancers. Ann Surg. 2017; 266(3): 457-462.
- 27Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14(4): 297-305.
- 28Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(10): 1385-1393.
- 29Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014; 15(12): 1303-1310.
- 30Weiss A, Cooley V, Al-Hilli Z, et al. Extrapolation of ACOSOG Z0011 trial results-A survey of breast cancer providers. Breast J. 2021; 27(6): 537-542.
- 31NCCN Network. Breast Cancer. Available from: https://www.nccn.org/guidelines/category_1. Accessed 20th October 2021.
- 32Tolaney SM, Barry WT, Dang CT, et al. Adjuvant Paclitaxel And Trastuzumab For Node-negative, HER2-positive breast cancer. N Engl J Med. 2015; 372(2): 134-141.
- 33Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273-1283.
- 34Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295(14): 1658-1667.
- 35Clarke M, Coates AS, Darby SC, et al, Early Breast Cancer Trialists' Collaborative Group (EBCTCG);. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008; 371(9606): 29-40.
- 36Kantor O, Ajmani G, Wang C-H, Datta A, Yao K. The shifting paradigm for breast cancer surgery in patients undergoing neoadjuvant chemotherapy. Ann Surg Oncol. 2018; 25(1): 164-172.
- 37Al-Hilli Z, Boughey JC, Hoskin TL, Heins CN, Hieken TJ. Increasing use of neoadjuvant treatment for T1 and T2 HER2-positive tumors. Ann Surg Oncol. 2015; 22(10): 3369-3375.
- 38Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24(9): 2278-2284.
- 39von Minckwitz G, Untch M, Blohmer J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15): 1796-1804.
- 40Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;Jan 13(1): 25-32.
- 41Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012; 379(9816): 633-640.
- 42Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012; 13(2): 135-144.
- 43Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020; 382(9): 810-821.
- 44Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938): 164-172.
- 45Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8): 1700-1712.
- 46Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017; 376(22): 2147-2159.
- 47von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380(7): 617-628.
- 48Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013; 14(7): 609-618.
- 49Boileau J-F, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study. J Clin Oncol. 2015;Jan 20 33(3): 258-264.
- 50Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26(5): 778-785.
- 51van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001; 19(22): 4224-4237.
- 52Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009; 27(15): 2474-2481.
- 53Robertson JF, Todd JH, Ellis IO, Elston CW, Blamey RW. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ. 1988; 297(6647): 511-514.
- 54Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol. 1994; 20(3): 207-214.
- 55Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol Off J Eur Soc. Med Oncol. 2003; 14(3): 414-420.
- 56Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001; 12(11): 1527-1532.
- 57Classe J-M, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019; 173(2): 343-352.
- 58Barrio AV, Mamtani A, Edelweiss M, et al. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy? Ann Surg Oncol. 2016; 23(11): 3475-3480. Available from http://www.ncbi.nlm.nih.gov/pubmed/27469123
- 59Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery. Available from: https://clinicaltrials.gov/ct2/show/NCT01872975. Accessed: 20th October 2021.
- 60Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017; 35(10): 1049-1060.
- 61Yang TJ, Morrow M, Modi S, et al. The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation. Ann Surg Oncol. 2015; 22(S3): 495-501.
- 62Moo T-A, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018; 25(6): 1488-1494.
- 63Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2): 460-469.
- 64Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016; 23(3): 749-756.
- 65Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study. Ann Surg Oncol. 2016; 23(11): 3467-3474.
- 66Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018; 379(2): 111-121.
- 67Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006; 3(10): 540-551.
- 68Kalinsky K, Barlow WE, Meric-Bernstam F, et al. Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer. General Session Abstracts. American Association for Cancer Research. 2021. https://10.1158/1538-7445.SABCS20-GS3-00
10.1158/1538-7445.SABCS20-GS3-00 Google Scholar
- 69Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012; 30(32): 3960-3966.
- 70Woodward WA, Barlow WE, Jagsi R, et al. Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer. JAMA Oncol. 2020; 6(4): 505-511.
- 71Profiling Early Breast Cancer for Radiotherapy Omission. Available from: Profiling Early Breast Cancer for Radiotherapy Omission. Accessed 20th October 2021.
- 72Individualized Decisions for Endocrine therapy Alone. Available from: Individualized Decisions for Endocrine therapy Alone. Accessed 20th October 2021.
- 73De-Escalation of Breast Radiation Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT04852887. Accessed 20th October 2021.
- 74Parulekar WR, Berrang T, Kong I, et al. Cctg MA.39 tailor RT: a randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). J Clin Oncol. 2019; 37(15_suppl): TPS602.
- 75 I-SPY2 Trial Available from: https://www.ispytrials.org/i-spy-platform/i-spy2. Accessed 20th October 2021.
- 76Barker A, Sigman C, Kelloff G, Hylton N, Berry D, Esserman L. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009; 86(1): 97-100.
- 77 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY). Available from: https://clinicaltrials.gov/ct2/show/NCT01042379?term=I+SpY%26;amp;draw=2%26;amp;rank=2. Accessed 20th October 2021.
- 78Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016; 375(1): 23-34.
- 79van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, et al. Minimally invasive complete response assessment of the breast after neoadjuvant systemic therapy for early breast cancer (MICRA trial): interim analysis of a multicenter observational cohort study. Ann Surg Oncol. 2021; 28(6): 3243-3253.
- 80Heil J, Pfob A, Sinn H-P, et al. Diagnosing pathologic complete response in the breast after neoadjuvant systemic treatment of breast cancer patients by minimal invasive biopsy: oral presentation at the san antonio breast cancer symposium on Friday, December 13, 2019, Program Number GS5-. Ann Surg. 2020.
10.1097/SLA.0000000000004246 Google Scholar
- 81Basik M, Costantino JP, De Los Santos JF, et al. NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility. J Clin Oncol. 2018; 36(15_suppl): TPS604.
10.1200/JCO.2018.36.15_suppl.TPS604 Google Scholar
- 82Tasoulis MK, Lee H-B, Yang W, et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg. 2020; 155(12):e204103.
- 83Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of low nodal positivity rate among patients with ERBB2 -positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 2018; 153(12): 1120-1126.
- 84Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017; 152(7): 665-670.
- 85Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy. Available from: https://clinicaltrials.gov/ct2/show/NCT04225858. Accessed 20th October 2021.
- 86Reimer T, Glass A, Botteri E, Loibl S, Gentilini D, Avoiding O. Axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: rationale for the prospective, multicentric EUBREAST-01 trial. Cancers (Basel). 2020; 12(12): 3698.
